Evidence map›Paper›PMID 27438462›Full record

ArticlePloS one2016

SILAC-MS Based Characterization of LPS and Resveratrol Induced Changes in Adipocyte Proteomics - Resveratrol as Ameliorating Factor on LPS Induced Changes.

Mark K Nøhr, Toke P Kroager, Kristian W Sanggaard, Anders D Knudsen, Allan Stensballe, Jan J Enghild, Jens Ølholm, Bjørn Richelsen, Steen B Pedersen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mark K NøhrInstitute of Clinical Medicine, Aarhus University, Aarhus, Denmark.ORCID http://orcid.org/0000-0002-5536-654X
Toke P KroagerLaboratory for Proteome Analysis and Protein Characterization, Department of Molecular Biology and Genetics and iNANO, Aarhus University, Aarhus, Denmark.
Kristian W SanggaardLaboratory for Proteome Analysis and Protein Characterization, Department of Molecular Biology and Genetics and iNANO, Aarhus University, Aarhus, Denmark.
Anders D KnudsenLaboratory for Proteome Analysis and Protein Characterization, Department of Molecular Biology and Genetics and iNANO, Aarhus University, Aarhus, Denmark.
Allan StensballeDepartment of Health Science and Technology, Aalborg University, Aalborg, Denmark.
Jan J EnghildLaboratory for Proteome Analysis and Protein Characterization, Department of Molecular Biology and Genetics and iNANO, Aarhus University, Aarhus, Denmark.
Jens ØlholmInstitute of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Bjørn RichelsenInstitute of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Steen B PedersenInstitute of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Aarhus University · DKAalborg University · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adipose tissue inflammation is believed to play a pivotal role in the development obesity-related morbidities such as insulin resistance. However, it is not known how this (low-grade) inflammatory state develops. It has been proposed that the leakage of lipopolysaccharides (LPS), originating from the gut microbiota, through the gut epithelium could drive initiation of inflammation. To get a better understanding of which proteins and intracellular pathways are affected by LPS in adipocytes, we performed SILAC proteomic analysis and identified proteins that were altered in expression. Furthermore, we tested the anti-inflammatory compound resveratrol. A total of 927 proteins were quantified by the SILAC method and of these 57- and 64 were significantly up- and downregulated by LPS, respectively. Bioinformatic analysis (GO analysis) revealed that the upregulated proteins were especially involved in the pathways of respiratory electron transport chain and inflammation. The downregulated proteins were especially involved in protein glycosylation. One of the latter proteins, GALNT2, has previously been described to regulate the expression of liver lipases such as ANGPTL3 and apoC-III affecting lipid metabolism. Furthermore, LPS treatment reduced the protein levels of the insulin sensitizing adipokine, adiponectin, and proteins participating in the final steps of triglyceride- and cholesterol synthesis. Generally, resveratrol opposed the effect induced by LPS and, as such, functioning as an ameliorating factor in disease state. Using an unbiased proteomic approach, we present novel insight of how the proteome is altered in adipocytes in response to LPS as seen in obesity. We suggest that LPS partly exerts its detrimental effects by altering glycosylation processes of the cell, which is starting to emerge as important posttranscriptional regulators of protein expression. Furthermore, resveratrol could be a prime candidate in ameliorating dysfunctioning adipose tissue induced by inflammatory stimulation.

Indexed as

AdipocytesAdipose TissueAngiopoietin-Like Protein 3Angiopoietin-like ProteinsAngiopoietinsGastrointestinal MicrobiomeGene Expression RegulationGlycosylationHumansInflammationInsulinInsulin ResistanceLipid MetabolismLipogenesisLipopolysaccharidesN-AcetylgalactosaminyltransferasesAngiopoietin-Like Protein 3Angiopoietin-like ProteinsAngiopoietinsANGPTL3 protein, humanInsulinLipopolysaccharidesN-AcetylgalactosaminyltransferasesPolypeptide N-acetylgalactosaminyltransferaseProteomeResveratrolStilbenes

Identifiers

PMID27438462
PMCPMC4954707
OpenAlexW2494174815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.